Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
The New England Journal of Medicine|May 15, 2009
Adjuvant chemotherapy in older women with early-stage breast cancerHyman B Muss, Donald A Berry, Constance T Cirrincione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2019
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 TrialHyman B Muss, Mei-Yin C Polley, Donald A Berry, et al.
JAMA Internal Medicine|December 12, 2025
Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical TrialKirkpatrick B Fergus, Katherine S Ross, Maren T Scheuner, et al.
JAMA|December 12, 2025
Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical TrialLaura J Esserman, Allison S Fiscalini, Arash Naeim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
Research Square|November 19, 2025
WISDOM Randomized Trial Comparing Risk-Based Versus Annual Breast Cancer Screening: Study Cohort Characteristics and DesignAllison Fiscalini, Kelly Blum, Kirkpatrick Fergus, et al.
NPJ Breast Cancer|May 23, 2026
WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and designAllison Fiscalini, Kelly Blum, Kirkpatrick Fergus, et al.
NPJ Breast Cancer|December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E Lang, Andres Forero-Torres, Douglas Yee, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
Pageof 10